Home › Funds › Paradigm Biocapital Advisors LP › OLMA

Paradigm Biocapital Advisors LP position in OLMA

OLEMA PHARMACEUTICALS INC · Health Care

Paradigm Biocapital Advisors LP reported holding 8,720,576 shares of OLMA (OLEMA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$75.3M, representing 1.50% of its reported portfolio and ranking #17 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed OLMA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)8.72M sh
Reported value held$75.35M
Portfolio Weight1.50%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's OLMA position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in OLMA in Q3 2023 at 7,803,600 shares (US$96.4M). The position peaked in Q4 2025 at 7,544,172 shares, worth US$188.6M. Across 13 filings, Paradigm Biocapital Advisors LP increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 8,720,576 shares valued at US$75.3M — an increase of 50,000 shares quarter over quarter.. Notable position changes include a 30% trim in Q3 2024 (shares fell 51% over the following quarter), a 33% increase in Q4 2024 (shares fell 36% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 7.80M $96.37M New
Q4 2023 7.90M $110.89M Add
Q1 2024 7.90M $89.47M Hold
Q2 2024 7.90M $85.52M Hold
Q3 2024 5.50M $65.71M Reduce
Q4 2024 7.30M $42.59M Add
Q1 2025 6.74M $25.35M Reduce
Q2 2025 6.76M $28.82M Hold
Q3 2025 6.79M $66.51M Hold
Q4 2025 7.54M $188.60M Add
Q1 2026 8.02M $119.59M Add
Q2 2026 8.67M $108.47M Add
Q3 2026 8.72M $75.35M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About OLMA and 13F data

OLMA (OLEMA PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in OLMA — the largest reported positions include BVF INC/IL (US$66.3M), Bain Capital Life Sciences Investors, LLC (US$61.2M), Siren, L.L.C. (US$42.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding OLMA

All OLMA fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held OLMA?

Paradigm Biocapital Advisors LP has disclosed OLMA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Paradigm Biocapital Advisors LP's current position in OLMA?

As of Q3 2026, Paradigm Biocapital Advisors LP holds 8.72M shares of OLMA (OLEMA PHARMACEUTICALS INC), valued at $75.35M, representing 1.50% of its reported portfolio and ranking #17.

Has Paradigm Biocapital Advisors LP been buying or selling OLMA?

In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in OLMA. The position peaked in Q4 2025 at 7.54M shares.

Which other funds hold OLMA?

Other major institutional holders of OLMA include BVF INC/IL, Bain Capital Life Sciences Investors, LLC, Siren, L.L.C., among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.